<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="0f08ec01-fce9-498e-810e-f74ad4ff24b2"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>These highlights do not include all the information needed to use GLYCOPYRROLATE TABLETS safely and effectively. See full prescribing information for GLYCOPYRROLATE TABLETS. GLYCOPYRROLATE tablets for oral use<br/> Initial U.S. Approval: 1961<br/>
   </title>
   <effectiveTime value="20250303"/>
   <setId root="6e5bfe6d-d321-4f0f-86e2-457d8fd10a6a"/>
   <versionNumber value="5"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="191427277" root="1.3.6.1.4.1.519.1"/>
            <name>Major Pharmaceuticals</name>
            <assignedEntity>
               <assignedOrganization/>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="59a4beca-ac42-49a1-823d-ff6b96ed75ea"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL product data elements section"/>
               <effectiveTime value="20221105"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="0904-6709" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Glycopyrrolate</name>
                        <formCode code="C42998" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Glycopyrrolate</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <asEquivalentEntity classCode="EQUIV">
                           <code code="C64637" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <definingMaterialKind>
                              <code code="23155-606" codeSystem="2.16.840.1.113883.6.69"/>
                           </definingMaterialKind>
                        </asEquivalentEntity>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="1"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="V92SO9WP2I" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>GLYCOPYRROLATE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="A14FB57V1D" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>GLYCOPYRRONIUM</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="O7TSZ97GEP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>DIBASIC CALCIUM PHOSPHATE DIHYDRATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="J2B2A4N98G" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>LACTOSE, UNSPECIFIED FORM</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MAGNESIUM STEARATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="FZ989GH94E" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POVIDONE, UNSPECIFIED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="5856J3G2A2" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM STARCH GLYCOLATE TYPE A POTATO</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43168" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BLISTER PACK"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="100"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="0904-6709-61" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20170227"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA207201" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20170227"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48325" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="WHITE" xsi:type="CE"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="7" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48348" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ROUND" xsi:type="CE"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="2" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">MCR;117</value>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="Section_1">
               <id root="53981c6e-7fd0-4532-baf8-9629b66495f1"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE</title>
               <text>
                  <paragraph> Glycopyrrolate is indicated in adults to reduce symptoms of a peptic ulcer as an adjunct to treatment of peptic ulcer.  <br/>
                     <br/>
                     <content styleCode="underline">Limitations of Use</content>
                     <br/> Glycopyrrolate is not indicated as monotherapy for the treatment of peptic ulcer because effectiveness in peptic ulcer healing has not been established.</paragraph>
               </text>
               <effectiveTime value="20221105"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Glycopyrrolate is anticholinergics indicated in adults to reduce symptoms of a peptic ulcer as an adjunct to treatment of peptic ulcer. </paragraph>
                        <paragraph>
                           <content styleCode="underline">Limitations of Use:</content>
                           <br/> Not indicated as monotherapy for the treatment of peptic ulcer because effectiveness in peptic ulcer healing has not been established. </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="Section_2">
               <id root="ac1821f5-d676-4c14-9c0f-486db7bc7650"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE AND ADMINISTRATION</title>
               <effectiveTime value="20221105"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Important Dosing Information (</content>
                           <linkHtml href="#Section_2.1">2.1</linkHtml>
                           <content styleCode="underline">)</content>
                        </paragraph>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>Glycopyrrolate tablets 2 mg are not recommended for patients initiating treatment or receiving maintenance treatment with glycopyrrolate tablets 1 mg or another 1 mg dosage strength of oral glycopyrrolate tablets.</item>
                        </list>
                        <paragraph>
                           <content styleCode="underline">Recommended Dosage (</content>
                           <linkHtml href="#Section_2.2">2.2</linkHtml>
                           <content styleCode="underline">)</content>
                        </paragraph>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>The recommended initial dosage of glycopyrrolate tablets 1 mg is 1 mg three times daily (in the morning, early afternoon, and at bedtime). Some patients may require 2 mg at bedtime to assure overnight control of symptoms. For maintenance, a dosage of 1 mg twice a day is frequently adequate.</item>
                           <item>
                              <caption>•</caption>The recommended dosage of glycopyrrolate tablets 2 mg for adults is 2 mg two or three times daily at equally spaced intervals.</item>
                           <item>
                              <caption>•</caption>The maximum recommended daily dosage is 8 mg.</item>
                           <item>
                              <caption>•</caption>Use the lowest effective dosage of glycopyrrolate to control symptoms. If patients can be titrated to a lower dose, switch from glycopyrrolate tablets 2 mg to glycopyrrolate tablets 1 mg or another 1 mg oral tablet of glycopyrrolate.</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="Section_2.1">
                     <id root="7c8c1230-236d-46da-9619-4adcb10030bb"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.1	Important Dosing Information</title>
                     <text>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>Glycopyrrolate tablets 2 mg are not recommended for patients in whom a lower dosage strength of oral glycopyrrolate (e.g., 1 mg tablet strength) is appropriate for initial or maintenance treatment because the dosage strength of glycopyrrolate tablets 2 mg may exceed the recommended initial and maintenance dosage of oral glycopyrrolate tablets.</item>
                        </list>
                     </text>
                     <effectiveTime value="20221105"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_2.2">
                     <id root="883f570b-b215-44d2-b764-c52e1921ebeb"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.2	Recommended Dosage</title>
                     <text>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>The recommended initial dosage of glycopyrrolate tablets 1 mg for adults is 1 mg three times daily (in the morning, early afternoon, and at bedtime). Some patients may require 2 mg at bedtime to assure overnight control of symptoms. For maintenance, a dosage of 1 mg twice a day is frequently adequate. </item>
                           <item>
                              <caption>•</caption>The recommended dosage of glycopyrrolate tablets 2 mg for adults is 2 mg two or three times daily at equally spaced intervals. </item>
                           <item>
                              <caption>•</caption>The maximum recommended daily dosage of glycopyrrolate is 8 mg. </item>
                           <item>
                              <caption>•</caption>Use the lowest effective dosage of glycopyrrolate to control symptoms. If patients can be titrated to a lower dose, switch from glycopyrrolate tablets 2 mg to glycopyrrolate tablets 1 mg or another 1 mg oral tablet of glycopyrrolate.</item>
                        </list>
                     </text>
                     <effectiveTime value="20221105"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_3">
               <id root="c4f14201-98d6-45be-8f9f-b498004ff376"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS AND STRENGTHS</title>
               <text>
                  <paragraph>Tablets: </paragraph>
                  <list listType="unordered">
                     <item>
                        <caption>•</caption>Glycopyrrolate Tablets USP, 1 mg are white to off-white, round, flat beveled edge tablet debossed with “MCR 117” separated by break line on one side and plain on other side. <br/>     Each tablet contains: Glycopyrrolate, USP 1 mg.</item>
                     <item>
                        <caption>•</caption>Glycopyrrolate Tablets USP, 2 mg are white to off white, round, flat beveled edge tablet debossed with “AC 108” separated by break line on one side and plain on other side.<br/>     Each tablet contains: Glycopyrrolate, USP 2 mg.</item>
                  </list>
               </text>
               <effectiveTime value="20221105"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>Tablets: 1 mg (functionally scored) and 2 mg (functionally scored) (<linkHtml href="#Section_3">3</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="Section_4">
               <id root="1eb3d48d-6b4e-4c6a-90a4-3ae373525462"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS</title>
               <text>
                  <paragraph> Glycopyrrolate tablets are contraindicated in:</paragraph>
                  <list listType="unordered">
                     <item>
                        <caption>•</caption> Patients at risk for anticholinergic toxicity due to an underlying medical condition, including:<list listType="unordered">
                           <item>
                              <caption>o</caption>Glaucoma [<content styleCode="italics">
                                 <linkHtml href="#Section_5.1">see Warnings and Precautions (5.1)</linkHtml>
                              </content>]</item>
                           <item>
                              <caption>o</caption>Obstructive uropathies, including prostatic hypertrophy</item>
                           <item>
                              <caption>o</caption>Mechanical obstructive diseases of the gastrointestinal tract (e.g., pyloroduodenal stenosis, strictures) [<content styleCode="italics">
                                 <linkHtml href="#Section_5.2">see Warnings and Precautions (5.2)</linkHtml>
                              </content>]</item>
                           <item>
                              <caption>o</caption>Gastrointestinal motility disorders (e.g., achalasia, paralytic ileus, intestinal atony)<content styleCode="italics"> [<linkHtml href="#Section_5.3">see Warnings and Precautions (5.3)</linkHtml>]</content>
                           </item>
                           <item>
                              <caption>o</caption>Bleeding gastrointestinal ulcer </item>
                           <item>
                              <caption>o</caption>Active inflammatory or infectious colitis which can lead to toxic megacolon </item>
                           <item>
                              <caption>o</caption>History of or current toxic megacolon </item>
                           <item>
                              <caption>o</caption>Myasthenia gravis </item>
                        </list>
                     </item>
                     <item>
                        <caption>•</caption>Patients with a hypersensitivity to glycopyrrolate or any of the inactive ingredients in glycopyrrolate tablets [<content styleCode="italics">
                           <linkHtml href="#_RefSection_6">see Adverse Reactions (6)</linkHtml> and <linkHtml href="#Section_11">Description (11)</linkHtml>
                        </content>].</item>
                  </list>
               </text>
               <effectiveTime value="20221105"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>Patients at risk for anticholinergic toxicity due to various underlying medical conditions. (<linkHtml href="#Section_4">4</linkHtml>, <linkHtml href="#Section_5.1">5.1</linkHtml>,<linkHtml href="#Section_5.2">5.2</linkHtml>, <linkHtml href="#Section_5.3">5.3</linkHtml>) </item>
                           <item>
                              <caption>•</caption>Hypersensitivity to glycopyrrolate or the inactive ingredients. (<linkHtml href="#Section_4">4</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="Section_5">
               <id root="1c9b9a23-b103-4dd0-ad2c-66ecb125d10a"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5 WARNINGS AND PRECAUTIONS</title>
               <effectiveTime value="20221105"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>
                              <content styleCode="underline">Precipitation of Acute Glaucoma:</content> May increase intraocular pressure; if symptoms occur, discontinue use and promptly seek medical care. (<linkHtml href="#Section_4">4</linkHtml>,<linkHtml href="#Section_5.1">5.1</linkHtml>)</item>
                           <item>
                              <caption>•</caption>
                              <content styleCode="underline">Partial or Complete Mechanical Intestinal Obstruction:</content> Diarrhea may be an early symptom, especially in patients with ileostomy or colostomy. If the obstruction is suspected, discontinue use and evaluate the patient for obstruction. (<linkHtml href="#Section_4">4</linkHtml>, <linkHtml href="#Section_5.2">5.2</linkHtml>)</item>
                           <item>
                              <caption>•</caption>
                              <content styleCode="underline">GI Adverse Reactions Due to Decreased GI Motility:</content> Delayed gastric emptying, constipation, and intestinal pseudo-obstruction may occur and precipitate or aggravate paralytic ileus and toxic megacolon; not recommended for use with anticholinergics or other medications that decrease GI peristalsis. (<linkHtml href="#Section_4">4</linkHtml>, <linkHtml href="#Section_5.3">5.3</linkHtml>, <linkHtml href="#Section_7.1">7.1</linkHtml>)</item>
                           <item>
                              <caption>•</caption>
                              <content styleCode="underline">Cognitive and Visual Adverse Reactions:</content> May impair mental and/or physical function. Inform patients not to operate motor vehicles or perform other hazardous tasks until reasonably certain they are not adversely affected; discontinue use if signs or symptoms develop. (<linkHtml href="#Section_5.4">5.4</linkHtml>,<linkHtml href="#Section_7.1">7.1</linkHtml>)</item>
                           <item>
                              <caption>•</caption>
                              <content styleCode="underline">Heat Prostration at High Environmental Temperatures:</content> Heat prostration resulting in fever and heatstroke can occur, especially in geriatric patients. Avoid exposure to hot or very warm environmental temperatures. (<linkHtml href="#Section_5.5">5.5</linkHtml>, <linkHtml href="#Section_5.7">5.7</linkHtml>)</item>
                           <item>
                              <caption>•</caption>
                              <content styleCode="underline">Other Conditions Exacerbated by Anticholinergic Adverse Reactions:</content> Use is not recommended in patients with autonomic neuropathy, hyperthyroidism, cardiac disease, hiatal hernia, etc. (<linkHtml href="#Section_5.6">5.6</linkHtml>, <linkHtml href="#Section_7.1">7.1</linkHtml>)</item>
                           <item>
                              <caption>•</caption>
                              <content styleCode="underline">Increased Risk of Anticholinergic Adverse Reactions in Geriatric Patients:</content> Complications include urinary retention, bowel obstruction, heat prostration, arrhythmias, delirium, and falls or fractures. Not recommended in geriatric patients and may be contraindicated in some patients with underlying medical conditions. (<linkHtml href="#Section_4">4</linkHtml>, <linkHtml href="#Section_5.7">5.7</linkHtml>, <linkHtml href="#Section_8.5">8.5</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="Section_5.1">
                     <id root="3cfd85c7-3dbc-4ca1-addd-685c2c91ffb7"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.1	Precipitation of Acute Glaucoma</title>
                     <text>
                        <paragraph>Glycopyrrolate may cause increased intraocular pressure in patients with glaucoma and reduce the effects of antiglaucoma agents. Instruct patients to discontinue glycopyrrolate tablets and promptly seek medical care if they experience symptoms of acute angle-closure glaucoma (pain and reddening of the eyes accompanied by dilated pupils) [<content styleCode="italics">
                              <linkHtml href="#Section_4">see Contraindications (4)</linkHtml>
                           </content>].</paragraph>
                     </text>
                     <effectiveTime value="20221105"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_5.2">
                     <id root="92b326f0-b458-49c0-bbe9-2a69242686f3"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.2	Partial or Complete Mechanical Intestinal Obstruction</title>
                     <text>
                        <paragraph>Glycopyrrolate may worsen intestinal mechanical obstruction, and diarrhea may be an early symptom of incomplete intestinal obstruction, especially in patients with ileostomy or colostomy. If partial or complete intestinal obstruction is suspected, discontinue the use of glycopyrrolate tablets and evaluate for potential intestinal obstruction [<content styleCode="italics">
                              <linkHtml href="#Section_4">see Contraindications (4</linkHtml>)</content>].</paragraph>
                     </text>
                     <effectiveTime value="20221105"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_5.3">
                     <id root="d537cfa2-e870-407e-8adb-136fc4a457d7"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.3	Gastrointestinal Adverse Reactions Due to Decreased Gastrointestinal Motility</title>
                     <text>
                        <paragraph>Glycopyrrolate reduces gastrointestinal motility and may result in delayed gastric emptying, constipation, and intestinal pseudo-obstruction and may precipitate or aggravate paralytic ileus and toxic megacolon [<content styleCode="italics">
                              <linkHtml href="#Section_4">see Contraindications (4</linkHtml>)</content>]. The risk of gastrointestinal adverse reactions is further increased with the use of other anticholinergics and other medications that decrease gastrointestinal peristalsis.<br/>
                           <br/> Monitor patients for symptoms of decreased gastrointestinal motility. Concomitant use of glycopyrrolate tablets and other anticholinergics or other medications that decrease GI peristalsis is not recommended <content styleCode="italics">[<linkHtml href="#Section_7.2">see Drug Interactions (7.2</linkHtml>)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20221105"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_5.4">
                     <id root="f8cf57e7-0730-4d08-b469-5935b736d451"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.4	Cognitive and Visual Adverse Reactions</title>
                     <text>
                        <paragraph>Glycopyrrolate may produce drowsiness and blurred vision and impair the mental and/or physical abilities required for the performance of hazardous tasks such as driving a motor vehicle, operating machinery, or performing other hazardous work [<content styleCode="italics">
                              <linkHtml href="#_RefSection_6">see Adverse Reactions (6</linkHtml>)</content>]. Concomitant use of other drugs that have anticholinergic properties may increase these effects [<content styleCode="italics">
                              <linkHtml href="#Section_7.1">see Drug Interactions (7.1)</linkHtml>
                           </content>]. <br/>
                           <br/> Inform patients not to operate motor vehicles or other dangerous machinery or perform other hazardous tasks until they are reasonably certain that glycopyrrolate tablets does not affect them adversely.</paragraph>
                        <paragraph>Discontinue glycopyrrolate tablets if signs or symptoms of cognitive or visual impairment develop.</paragraph>
                     </text>
                     <effectiveTime value="20221105"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_5.5">
                     <id root="692bc3e7-bec7-450d-a6e8-d3f0f456b527"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.5	Heat Prostration at High Environmental Temperatures</title>
                     <text>
                        <paragraph>In the presence of a high environmental temperature, heat prostration resulting in fever and heatstroke can occur with the use of glycopyrrolate tablets due to decreased sweating, particularly in geriatric patients [<content styleCode="italics">
                              <linkHtml href="#_RefSection_6">see Adverse Reactions (6)</linkHtml>
                           </content>]. Advise patients to avoid exposure to hot or very warm environmental temperatures when taking glycopyrrolate tablets. Glycopyrrolate tablets are not recommended in geriatric patients [<content styleCode="italics">
                              <linkHtml href="#Section_5.7">see Warnings and Precautions (5.7</linkHtml>)</content>].</paragraph>
                     </text>
                     <effectiveTime value="20221105"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_5.6">
                     <id root="6e3d35a3-714a-48bb-b8e4-f062052284d3"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.6	Other Conditions Exacerbated by Anticholinergic Adverse Reactions</title>
                     <text>
                        <paragraph>Glycopyrrolate tablets are not recommended in patients with other conditions exacerbated by anticholinergic adverse reactions (e.g., autonomic neuropathy, hyperthyroidism, cardiac disease, and hiatal hernia associated with reflux esophagitis) and in patients taking other anticholinergic medications [<content styleCode="italics">
                              <linkHtml href="#Section_7.1">see Drug Interactions (7.1)</linkHtml>
                           </content>].</paragraph>
                     </text>
                     <effectiveTime value="20221105"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_5.7">
                     <id root="a2a499a4-05c2-4bf9-b5da-37f18811675e"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.7	Increased Risk of Anticholinergic Adverse Reactions in Geriatric Patients</title>
                     <text>
                        <paragraph>Geriatric patients 65 years of age and older are at increased risk of anticholinergic adverse reactions that may lead to complications of urinary retention, bowel obstruction, heat prostration, arrhythmias, delirium, and falls or fractures. Glycopyrrolate tablets are not recommended in geriatric patients and may be contraindicated in some geriatric patients with underlying medical conditions [<content styleCode="italics">
                              <linkHtml href="#Section_4">see Contraindications (4</linkHtml>), <linkHtml href="#Section_5.2">Warnings and Precautions (5.2</linkHtml>, <linkHtml href="#Section_5.5">5.5</linkHtml>), <linkHtml href="#_RefSection_6">Adverse Reactions (6)</linkHtml> and <linkHtml href="#Section_8.5">Use in Specific Populations (8.5)</linkHtml>
                           </content>].</paragraph>
                     </text>
                     <effectiveTime value="20221105"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_6">
               <id root="30d8828d-1efc-4000-a0d0-cc54c94d6f0e"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS</title>
               <text>
                  <paragraph>The following serious or otherwise important adverse reactions are discussed elsewhere in the labeling:</paragraph>
                  <list listType="unordered">
                     <item>
                        <caption>•</caption>Precipitation of Acute Glaucoma [<content styleCode="italics">
                           <linkHtml href="#Section_5.1">see Warnings and Precautions (5.1)</linkHtml>
                        </content>]</item>
                     <item>
                        <caption>•</caption>Partial or Complete Mechanical Intestinal Obstruction [<content styleCode="italics">
                           <linkHtml href="#Section_5.2">see Warnings and Precautions (5.2</linkHtml>)</content>]</item>
                     <item>
                        <caption>•</caption>Gastrointestinal Adverse Reactions due to Decreased Gastrointestinal Motility [<content styleCode="italics">
                           <linkHtml href="#Section_5.3">see Warnings and Precautions (5.3)</linkHtml>
                        </content>]</item>
                     <item>
                        <caption>•</caption>Cognitive and Visual Adverse Reactions [<content styleCode="italics">
                           <linkHtml href="#Section_5.4">see Warnings and Precautions (5.4</linkHtml>
                        </content>)]</item>
                     <item>
                        <caption>•</caption>Heat Prostration at High Environmental Temperatures [<content styleCode="italics">
                           <linkHtml href="#Section_5.5">see Warnings and Precautions (5.5)</linkHtml>
                        </content>]</item>
                     <item>
                        <caption>•</caption>Other Conditions Exacerbated by Anticholinergic Adverse Reactions [<content styleCode="italics">
                           <linkHtml href="#Section_5.6">see Warnings and Precautions (5.6)</linkHtml>
                        </content>]</item>
                     <item>
                        <caption>•</caption>Increased Risk of Anticholinergic Adverse Reactions in Geriatric Patients [<content styleCode="italics">
                           <linkHtml href="#Section_5.7">see Warnings and Precaution (5.7)</linkHtml>
                        </content>]</item>
                  </list>
                  <paragraph> The following adverse reactions associated with the use of glycopyrrolate, or other anticholinergic drugs, were identified in clinical studies or postmarketing reports. Because some of these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</paragraph>
                  <paragraph>
                     <content styleCode="italics">Cardiac Disorders:</content> chest, pain, hypertension, tachycardia<br/>
                     <content styleCode="italics">Endocrine Disorders:</content> decreased sweating<br/>
                     <content styleCode="italics">Eye Disorders:</content> blurred vision, cycloplegia, dilatation of the pupil, increased ocular tension<br/>
                     <content styleCode="italics">Gastrointestinal Disorders:</content> bloated feeling, constipation, dry mouth, dysgeusia, nausea, vomiting<br/>
                     <content styleCode="italics">Immune System Disorders:</content> anaphylaxis [<content styleCode="italics">
                        <linkHtml href="#Section_4">see Contraindications (4)</linkHtml>
                     </content>]<br/>
                     <content styleCode="italics">Nervous System Disorders:</content> agitation, dizziness, drowsiness, headache, insomnia, mental confusion, nervousness, weakness<br/>
                     <content styleCode="italics">Respiratory Disorders:</content> respiratory depression, throat irritation<br/>
                     <content styleCode="italics">Renal and Urinary Disorders:</content> urinary hesitancy, urinary retention<br/>
                     <content styleCode="italics">Reproductive System and Breast Disorders:</content> impotence, suppression of lactation<br/>
                     <content styleCode="italics">Vascular Disorders:</content> flushing<br/>
                  </paragraph>
               </text>
               <effectiveTime value="20221105"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>
                           <content styleCode="bold">Adverse reactions include blurred vision, drowsiness, decreased sweating, flushing, vomiting, constipation, dry mouth, tachycardia, and urinary retention. (</content>
                           <linkHtml href="#_RefSection_6">6</linkHtml>
                           <content styleCode="bold">)To report SUSPECTED ADVERSE REACTIONS, contact Avet Pharmaceuticals Inc. at 1-866-901-3784 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch</content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="Section_7">
               <id root="4c4805fe-a591-4a2e-a868-1a26c81fee1f"/>
               <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
               <title>7 DRUG INTERACTIONS</title>
               <effectiveTime value="20221105"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>
                              <content styleCode="underline">Other Anticholinergic Drugs:</content> Concomitant use is not recommended. (<linkHtml href="#Section_5.3">5.3</linkHtml>, <linkHtml href="#Section_5.4">5.4</linkHtml>, <linkHtml href="#Section_5.6">5.6</linkHtml>, <linkHtml href="#Section_7.1">7.1</linkHtml>)</item>
                           <item>
                              <caption>•</caption>
                              <content styleCode="underline">Drugs with Altered Absorption due to Decreased GI Motility:</content> Concomitant use is not recommended. (<linkHtml href="#Section_7.2">7.2</linkHtml>)</item>
                           <item>
                              <caption>•</caption>
                              <content styleCode="underline">GI Toxicity with Solid Oral Dosage Forms of Potassium Chloride:</content> Concomitant use is not recommended. (<linkHtml href="#Section_7.3">7.3</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="Section_7.1">
                     <id root="8703401f-48a6-4b66-8235-ec61810f713a"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.1	Other Anticholinergic Drugs</title>
                     <text>
                        <paragraph>There is potential for an additive interaction between glycopyrrolate and concomitantly used anticholinergic drugs (e.g., tricyclic antidepressants, anti-epileptics, class I antiarrhythmics, anti-spasmodics, amantadine) resulting in increased anticholinergic adverse reactions. Co-administration of antipsychotics with glycopyrrolate may lead to worsening of tardive dyskinesia. Glycopyrrolate tablets are not recommended in patients taking other anticholinergic drugs [<content styleCode="italics">
                              <linkHtml href="#Section_5.3">see Warnings and Precautions (5.3</linkHtml>, <linkHtml href="#Section_5.4">5.4</linkHtml>, <linkHtml href="#Section_5.6">5.6)</linkHtml>
                           </content>].</paragraph>
                     </text>
                     <effectiveTime value="20221105"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_7.2">
                     <id root="b8f45558-ae20-4ea8-a1f2-97c3c64ca8b8"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.2	Drugs with Altered Absorption due to Decreased Gastrointestinal Motility and Increased Transit Time</title>
                     <text>
                        <paragraph>Decreased gastrointestinal motility by glycopyrrolate may impact absorption of other drugs leading to increased or decreased drug exposure. Glycopyrrolate tablets are not recommended in patients taking other drugs that are affected by altered gastrointestinal motility [<content styleCode="italics">
                              <linkHtml href="#Section_5.3">see Warnings and Precautions (5.3)</linkHtml>
                           </content>].</paragraph>
                     </text>
                     <effectiveTime value="20221105"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_7.3">
                     <id root="3c179d7b-8470-4e0f-81e5-0ba53a3e06a3"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.3	Gastrointestinal Toxicity with Solid Dosage Forms of Potassium Chloride</title>
                     <text>
                        <paragraph>Oral glycopyrrolate may worsen gastrointestinal mucosal injury reported with solid oral dosage forms of potassium chloride due to decreased gastric motility and increased transit time, leading to prolonged contact with the gastrointestinal mucosa. Glycopyrrolate tablets are not recommended in patients taking solid oral dosage forms of potassium chloride.</paragraph>
                     </text>
                     <effectiveTime value="20221105"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_8">
               <id root="9a6c5635-938b-4750-92a1-faa7e187b699"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS</title>
               <effectiveTime value="20221105"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>
                              <content styleCode="underline">Renal Impairment:</content> Monitor patients with renal impairment; if anticholinergic adverse reactions occur, discontinue use. (<linkHtml href="#Section_8.6">8.6</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="Section_8.1">
                     <id root="e0274142-7ca8-43c1-bf6c-6434b952afd4"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1 Pregnancy</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Risk Summary</content> <br/> Over decades of use, there is an absence of published data on orally administered glycopyrrolate in pregnant women, including an absence of any reports of a drug-associated risk of major birth defects, miscarriage, or other adverse maternal or fetal outcomes. In animal studies, at non-maternally toxic doses of oral glycopyrrolate, there were no adverse developmental effects in rats or rabbits. A pre- and post-natal development study of oral glycopyrrolate in rats showed a decrease in pup mean bodyweight that recovered post nursing, with no other developmental effects observed (<content styleCode="italics">
                              <linkHtml href="#Section_8.1">see Data</linkHtml>
                           </content>).<br/>
                           <br/> The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.<br/>
                           <br/>
                           <content styleCode="underline">Data</content>
                           <br/>
                           <br/>
                           <content styleCode="italics">Animal Data</content>
                           <br/>
                           <br/> At non-maternally toxic doses of oral glycopyrrolate, there were no effects on embryo-fetal development or toxicity in rats or rabbits. A pre- and post-natal development study of oral glycopyrrolate in rats showed a decrease in pup mean bodyweight that recovered post nursing, with no other developmental effects observed. <br/>
                           <br/> In a published reproductive and developmental study, male and female rats were administered glycopyrrolate in the diet at 0 mg/kg/day, 32.5 mg/kg/day, 63 mg/kg/day, and 130 mg/kg/day for 3 weeks to 5 weeks and through up to three consecutive litters. There was no indication of abnormalities in the pups of treated dams. There was a decreased rate of conception and in survival rate at weaning for all treated animals in a dose-related manner. Diminished rates of conception may be due to diminished seminal secretion [<content styleCode="italics">
                              <linkHtml href="#Section_13.1">see NonclinicalToxicology (13.1)</linkHtml>
                           </content>].</paragraph>
                     </text>
                     <effectiveTime value="20221105"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_8.2">
                     <id root="f8cf237c-1b84-4ec1-bec2-fbbec2a14aa9"/>
                     <code code="34079-4" codeSystem="2.16.840.1.113883.6.1" displayName="LABOR &amp; DELIVERY SECTION"/>
                     <title>8.2  Lactation</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Risk Summary</content>
                           <br/> There are no data on the presence of glycopyrrolate in either human or animal milk, the effects on the breastfed infant, or the effects on milk production. As with other anticholinergic drugs, glycopyrrolate may cause suppression of lactation. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for glycopyrrolate tablets and any potential adverse effects on the breastfed infant from glycopyrrolate tablets.</paragraph>
                     </text>
                     <effectiveTime value="20221105"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_8.4">
                     <id root="c3e1dea4-0bfe-461d-9249-e108dd7882ab"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4 Pediatric Use</title>
                     <text>
                        <paragraph>Safety and effectiveness in pediatric patients have not been established.</paragraph>
                     </text>
                     <effectiveTime value="20221105"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_8.5">
                     <id root="496b9c46-42da-432a-a514-9cdeb3b67fcc"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>8.5 Geriatric Use</title>
                     <text>
                        <paragraph>Geriatric patients 65 years of age and older may be more sensitive to the anticholinergic adverse reactions of glycopyrrolate leading to complications of urinary retention, bowel obstruction, heat prostration, arrhythmias, delirium, and falls or fractures; therefore, glycopyrrolate tablets are not recommended in geriatric patients and may be contraindicated in some geriatric patients with underlying medical conditions [<content styleCode="italics">
                              <linkHtml href="#Section_4">see Contraindications (4)</linkHtml> and <linkHtml href="#Section_5">Warnings and Precautions (5)</linkHtml>
                           </content>].</paragraph>
                     </text>
                     <effectiveTime value="20221105"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_8.6">
                     <id root="ca752573-8607-4814-b91f-1cf53dfd2917"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>8.6	Renal Impairment</title>
                     <text>
                        <paragraph>Glycopyrrolate is substantially excreted by the kidney [<content styleCode="italics">
                              <linkHtml href="#Section_12.3">see Clinical Pharmacology (12.3)</linkHtml>
                           </content>]. Monitor patients with renal impairment for anticholinergic adverse reactions [<content styleCode="italics">
                              <linkHtml href="#_RefSection_6">see Adverse Reactions (6)</linkHtml>
                           </content>]. If anticholinergic adverse reactions occur, discontinue glycopyrrolate tablets.</paragraph>
                     </text>
                     <effectiveTime value="20221105"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_10">
               <id root="01727fb5-b7e1-48a4-91e7-358d5ebc1631"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>10 OVERDOSAGE</title>
               <text>
                  <paragraph>Signs and symptoms of glycopyrrolate overdosage are related to excessive anti-muscarinic anticholinergic activity and are generally peripheral (e.g., flushing, hyperthermia, tachycardia, ileus, urinary retention, loss of ocular accommodation, and light sensitivity due to mydriasis), but central nervous system toxicity (agitation, seizures, hyperthermia) may also occur. <br/>
                     <br/>
                     <content styleCode="italics">If over-exposure occurs, call the Poison Control Center at 1-800-222-1222 for current information on the management of glycopyrrolate poisoning and overdosage. </content>
                     <br/>
                     <br/> Management of glycopyrrolate overdosage is based upon presenting signs and symptoms, including close observation for severe or life-threatening complications which may require respiratory and cardiovascular monitoring and support. Consider administration of activated charcoal and/or use of a reversible anticholinesterase as appropriate or recommended by Poison Control.</paragraph>
               </text>
               <effectiveTime value="20221105"/>
            </section>
         </component>
         <component>
            <section ID="Section_11">
               <id root="bccd7cdf-d8e2-4c36-b6a1-9562b02001f1"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION</title>
               <text>
                  <paragraph>Glycopyrrolate tablets contain synthetic anticholinergic glycopyrrolate. Glycopyrrolate is a quaternary ammonium compound with the following chemical name: 3-[(cyclopentyl hydroxyphenylacetyl)oxy]-1,1-dimethylpyrrolidinium bromide. The molecular formula for glycopyrrolate is C<sub>19</sub>H<sub>28</sub>BrNO<sub>3</sub>, the molecular weight is 398.3 g/mol, and the structural formula is:</paragraph>
                  <renderMultiMedia ID="id854" referencedObject="MM1"/>
                  <paragraph> Each glycopyrrolate tablets, USP contains glycopyrrolate, USP 1 mg or 2 mg as the active ingredient. The inactive ingredients are dibasic calcium phosphate, lactose, magnesium stearate, povidone, and sodium starch glycolate.</paragraph>
               </text>
               <effectiveTime value="20221105"/>
               <component>
                  <observationMedia ID="MM1">
                     <text>glycco-structure</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="glyco-structure.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_12">
               <id root="d1e865d9-1a26-43cf-b54e-8a3247548f45"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY</title>
               <effectiveTime value="20221105"/>
               <component>
                  <section ID="Section_12.1">
                     <id root="4c6222c1-1dd2-45f6-b274-97255c509502"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1 Mechanism of Action</title>
                     <text>
                        <paragraph>Glycopyrrolate, an anticholinergic (antimuscarinic) agent, inhibits the action of acetylcholine on parietal cells in the stomach and decreases the volume and acidity of gastric secretions.</paragraph>
                     </text>
                     <effectiveTime value="20221105"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_12.2">
                     <id root="5a020bca-e10c-4127-9529-81d267d7c2d9"/>
                     <code code="43681-6" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACODYNAMICS SECTION"/>
                     <title>12.2 Pharmacodynamics</title>
                     <text>
                        <paragraph>No formal pharmacodynamic studies have been conducted with glycopyrrolate.</paragraph>
                     </text>
                     <effectiveTime value="20221105"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_12.3">
                     <id root="4698996d-c506-415f-9d0c-aca16cc1c97a"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3 Pharmacokinetics</title>
                     <text>
                        <paragraph>
                           <content styleCode="italics">Patients with Renal Impairment</content> <br/>
                           <br/> In the published literature, glycopyrrolate 4 mcg/kg was administered intravenously (glycopyrrolate tablets are not recommended for intravenous use) in uremic patients undergoing renal transplantation surgery. The mean AUC (10.6 mcg·h/L) and 24-hour urinary excretion (7%) for glycopyrrolate were significantly different from normal healthy adult subjects undergoing general surgery (3.7 mcg·h/L, and 65%, respectively) [<content styleCode="italics">
                              <linkHtml href="#Section_8.6">see Use in Specific Populations (8.6)</linkHtml>
                           </content>].</paragraph>
                     </text>
                     <effectiveTime value="20221105"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_13">
               <id root="0472c2f5-a5b6-4b2d-852d-f7c2109115d0"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13 NONCLINICAL TOXICOLOGY</title>
               <effectiveTime value="20221105"/>
               <component>
                  <section ID="Section_13.1">
                     <id root="12f27b74-1f44-4985-a181-755c10dc4525"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>13.1Carcinogenesis, Mutagenesis, Impairment of Fertility</title>
                     <text>
                        <paragraph>Reproduction studies in rats resulted in diminished rates of conception in a dose-related manner. Studies in dogs suggest that diminished rates of conception may be due to diminished seminal secretion, which is evident at high doses of glycopyrrolate.</paragraph>
                     </text>
                     <effectiveTime value="20221105"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_17">
               <id root="c0481dac-0d18-44c8-bdc6-75c35d8660a6"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIED/STORAGE AND HANDLING</title>
               <text>
                  <paragraph>Glycopyrrolate Tablets USP, 1 mg are white to off-white, round, flat beveled edge tablet debossed with “MCR 117” separated by break line on one side and plain on other side. Packaged:</paragraph>
                  <paragraph>Carton of 100 tablets (10 tablets each blister pack x 10), NDC 0904-6709-61</paragraph>
                  <paragraph>Store at 20° to 25°C (68° to 77°F); excursions permitted between 15° C to 30°C (59° F to 86°F) [see USP Controlled Room Temperature]. Keep out of reach of children.<br/>
                     <br/> Dispense in tight container.</paragraph>
               </text>
               <effectiveTime value="20221105"/>
            </section>
         </component>
         <component>
            <section ID="Section_16">
               <id root="74996492-b49f-424e-9c1c-f547b2703913"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17 PATIENT COUNSELING INFORMATION</title>
               <text>
                  <paragraph>
                     <content styleCode="underline">Precipitation of Acute Glaucoma</content>
                     <br/> Advise patients to discontinue glycopyrrolate tablets and promptly seek medical care if they experience symptoms of acute angle-closure glaucoma (pain and reddening of the eyes accompanied by dilated pupils) [<content styleCode="italics">
                        <linkHtml href="#Section_5.1">see Warnings and Precautions (5.1)</linkHtml>
                     </content>].<br/>
                     <br/>
                     <content styleCode="underline">Partial or Complete Mechanical Intestinal Obstruction</content>
                     <br/> Advise patients to contact their healthcare provider if diarrhea occurs, especially in patients with ileostomy or colostomy [<content styleCode="italics">
                        <linkHtml href="#Section_5.2">see Warnings and Precautions (5.2)</linkHtml>
                     </content>].<br/>
                     <br/>
                     <content styleCode="underline">Gastrointestinal Adverse Reactions Due to Decreased Gastrointestinal Motility</content>
                     <br/> Inform patients that glycopyrrolate tablets may cause adverse reactions related to decreased gastrointestinal motility and report to their healthcare provider if they experience symptoms such as vomiting, early satiety, abdominal distention, and constipation [<content styleCode="italics">
                        <linkHtml href="#Section_5.3">see Warnings and Precautions (5.3)</linkHtml>
                     </content>].<br/>
                     <br/>
                     <content styleCode="underline">Cognitive and Visual Adverse Reactions</content>
                     <br/> Inform patients that glycopyrrolate tablets may cause cognitive or visual impairment and not operate motor vehicles or other dangerous machinery or perform other hazardous tasks until they are reasonably certain that glycopyrrolate tablets do not affect them adversely. Advise patients to discontinue glycopyrrolate tablets immediately and contact their healthcare provider if symptoms develop (e.g., drowsiness or blurred vision) [<content styleCode="italics">
                        <linkHtml href="#Section_5.4">see Warnings and Precautions (5.4)</linkHtml>
                     </content>].<br/>
                     <br/>
                     <content styleCode="underline">Heat Prostration at High Environmental Temperatures</content> <br/> Inform patients that glycopyrrolate tablets can reduce sweating, leading to the possibility of heat exhaustion or heat stroke. Advise patients to avoid exposure to hot or very warm environmental temperatures [<content styleCode="italics">
                        <linkHtml href="#Section_5.5">see Warnings and Precautions (5.5)</linkHtml>
                     </content>].</paragraph>
                  <paragraph>
                     <content styleCode="bold">Distributed by:</content>
                     <br/> Avet Pharmaceuticals Inc.<br/> East Brunswick, NJ 08816<br/> 1.866.901.DRUG (3784)</paragraph>
                  <renderMultiMedia ID="id978" referencedObject="MM2"/>
                  <paragraph>
                     <content styleCode="bold">Packaged and Distributed by:</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">MAJOR® PHARMACEUTICALS</content>
                  </paragraph>
                  <paragraph>Indianapolis, IN 46268 USA</paragraph>
                  <paragraph>Refer to package label for Distributor's NDC Number</paragraph>
                  <paragraph>
                     <content styleCode="bold">200146</content>
                     <br/>
                     <content styleCode="bold"> Revised: 10/2022</content>
                  </paragraph>
               </text>
               <effectiveTime value="20221105"/>
               <component>
                  <observationMedia ID="MM2">
                     <text>avet-logo-spl</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="avet-logo-spl.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_84fbc107-3065-4970-8600-81caf6dece89">
               <id root="56c42d82-0c59-4724-b675-49b5e11bdb22"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>Package/Label Display Panel </title>
               <text>
                  <paragraph>MAJOR®</paragraph>
                  <paragraph>NDC 0904-6709-61</paragraph>
                  <paragraph>Unit Dose</paragraph>
                  <paragraph>
                     <content styleCode="bold">Glycopyrrolate</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Tablets, USP</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">1 mg</content>
                  </paragraph>
                  <paragraph>100 TABLETS (10 x 10)</paragraph>
                  <paragraph>Rx only</paragraph>
                  <renderMultiMedia ID="id546119768" referencedObject="ID_9fca7649-bb53-40d8-8411-f36a28691996"/>
               </text>
               <effectiveTime value="20221105"/>
               <component>
                  <observationMedia ID="ID_9fca7649-bb53-40d8-8411-f36a28691996">
                     <text>1mg carton label</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="83836cd6-026c-4163-bf62-661d0920f8ce-00.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>